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Abstract 
Background: Paclitaxel-coated balloon (PCB) angioplasty in small vessel de novo lesions has favourable outcome 
and appears to be an alternative to stent implantation. However there is limitted data on its use specifically in small 
vessel acute coronary syndrome (ACS).
Methods: We analyse patients data from the SeQuent Please Small Vessel ‘PCB only’ Registry. It was an interna-
tional, prospective, multicentre registry which enrolled patients with de novo lesions of small vessel diameter (≥2.0, 
≤2.75 mm). Patients were divided into the ACS group and the non-ACS group and comparison made between the 
two groups. The primary end-point was clinically driven target lesion revascularisation (TLR) at 9 months. Secondary 
end-points were acute technical success, 30-day and 9-month major adverse cardiac events (death, myocardial infarc-
tion or TLR) (MACE) and the occurence of definite lesion and vessel thrombosis.
Results: A total of 447 patients were enrolled for this registry of which 105 (23.5 %) patients were ACS (STEMI and 
NSTEMI). The procedural success rate was 98.1 % in ACS group. The mean vessel diameter for the ACS and non-ACS 
group were 2.15 ± 0.36 and 2.14 ± 0.35 respectively. Similar mean lesion length of around 15.5 mm was recorded 
in both groups. Additional stenting was required in 9.3 % ACS and 6.5 % non-ACS, p = 0.308. Reasons for additional 
stenting were target lesion related dissection (57.6 %) or non-target lesion stenosis (41.2 %). More than half of the 
patients had 4 weeks of aspirin/clopidogrel (57.1 % ACS, 60.5 % non-ACS). No significant difference between the ACS 
and non-ACS groups with regards to the duration and types of DAPT during follow up. At 30-day, MACE rate were 
(0 % ACS vs 0.3 % non-ACS, p = 0.599). At 9 months TLR rates were (1.2 % ACS vs 4.3 % non-ACS, p = 0.180) and MACE 
rates (3.6 % ACS vs 5.0 % non-ACS, p = 0.601).
Conclusion: PCB in ACS with small vessel de novo lesions has low 30-day and 9-month TLR/MACE rates comparable 
to non-ACS small vessels. Thus it appears to be an alternative to stent implantation in the treatment ACS.
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Background
Paclitaxel coated balloon (PCB) angioplasty has proven 
benefit in the treatment of bare-metal and drug-eluting 
in-stent restenosis (ISR) (Scheller et al. 2006, 2008, 2012; 
Harbara et al. 2011; Byrne et al. 2013). The efficacy of PCB 
in treating small vessel de-novo lesions is also emerging 
with promising data so far (Ali et al. 2011; Zeymer et al. 
2014). However, the data on PCB angioplasty specifically 
in acute coronary syndrome (ACS) is still lacking. Intra-
vascular plaque rupture and thrombus formation in ACS 
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cast doubt on the effectiveness of paclitaxel drug to be ade-
quately delivered to the vessel wall. However, the increased 
risk of in-stent thrombosis and restenosis in small vessel 
PCI with stents (Akiyama et al. 1998; Kasaoka et al. 1998) 
has made PCB angioplasty, which leaves no intravascular 
metal a good alternative in theory. Therefore we utilise 
patients data from a prospective ‘real world’ registry to 
determine the feasibility of PCB angioplasty in acute coro-
nary syndrome of small vessel de-novo lesions by means 
of major adverse cardiac event (MACE) and target lesion 
revascularisation (TLR) at 30-day and 9 months follow up.
Methods
Centres
Prospective patients enrolment was done in Germany (20 
centres), Malaysia (4 centres), Singapore (3 centres), Italy 
(2 centres), France (1 centre), Finland (1 centre), Poland 
(1 centre), China (1 centre) and Iran (1 centre). The 
study was approved by the individual institutional review 
boards of the participating centres.
Materials
In this registry the paclitaxel coated percutaneous trans-
luminal coronary angioplasty (PTCA) catheter based on 
the Paccocath Technology (SeQuent Please, B. Braun 
Melsungen AG) was used.
Inclusion and exclusion criteria
Patients ≥18  years of age with de novo small vessel 
lesions (2.0–2.75  mm diameter) and stable angina, doc-
umented ischemia (non-ACS) and acute coronary syn-
drome (ACS) were recruited for this registry. There were 
no patient exclusion criteria except those associated with 
contraindications for anti-platelet therapy.
Procedural approach
It was the purpose of this registry to treat de novo lesions 
with the PCB catheter only without additional stent 
implantations, according to the German Consensus Group 
recommendations (Kleber et  al. 2011). Predilatation with 
an uncoated balloon catheter according to the above men-
tioned recommendation was mandatory (Kleber et  al. 
2011). In cases of severe dissections or unsatisfactory 
results post-PCB, the implantation of a BMS was recom-
mended and left to the discretion of the interventionalist.
Vascular access was from the femoral or radial route 
with recommended diagnostic catheter of at least 5 
French in diameter. Due to the ‘all-comers’ nature of this 
registry, efforts were made to not interfere with estab-
lished national co-medication recommendations. Dual 
anti-platelet therapy (DAPT) with acetylsalicylic acid 
(aspirin) and an ADP receptor inhibitor (clopidogrel, 
prasugrel, or ticagrelor) was recommended, but at the 
discretion of the treating physician. An injectable antico-
agulant was advised on the basis of local routines in the 
participating catheterisation laboratories.
Postprocedural medication
An ADP receptor antagonist (clopidogrel 75  mg/day, 
prasugrel 10 mg/day or ticagrelor 180 mg/day) was rec-
ommended for either 1, 3–6 or 12 months together with 
aspirin 100–325 mg/day at the discretion of the treating 
physician.
Definitions
MACE included TLR, myocardial revascularisation, and 
death of cardiac or unknown origin. MI was diagnosed 
with corresponding ECG changes and/or cardiac enzyme 
elevations according to each institution’s routine diag-
nostic algorithms.
End points
Clinically driven TLR (either by re-do PCI or CABG) 
at 9 months post procedure was the primary end point. 
Secondary end points were procedural success rate, defi-
nite acute/sub-acute vessel thrombosis rates based on the 
Academic Research Consortium (ARC) criteria (Cutlip 
et  al. 2007) and major adverse cardiac events (MACE) 
as the composite of TLR, cardiac death, and myocardial 
infarction.
Data collection
Baseline and clinical follow-up data were collected 
through a web based data acquisition system between 
June 2011 and December 2012. Follow up data were 
typically collected during routine visits with the treat-
ing physician. National principal investigators (one per 
country) were responsible for the accuracy of their data-
sets. Source data verification was done when the rou-
tinely performed web based plausibility checks indicated 
discrepancies.
Statistical analysis
Categorical variables were evaluated with the χ2 test. 
Continuous variables were typically compared with the 
unpaired two-tailed Student’s t test. In parameters with 
Gaussian distributions, samples were described using the 
mean and the SD. SPSS V.20.0 (IBM, Munich, Germany) 
was used for all analyses at a significance level α of 0.05.
Results
Patients demographics and presentation
A total of 471 PCB angioplasties were performed in 
447 patients of which 113 (25  %) were ACS (STEMI/
NSTEMI). A small proportion of patients (7.2  %) had 
bail-out BMS stenting. Patients baseline characteristics 
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are shown in Table  1. All clinical characteristics were 
similar in the ACS and non-ACS groups except for 
hyperlipidaemia and previous PCI where the non-ACS 
group had higher rates for both.
Lesion characteristics and procedural data
The mean vessel diameter for the ACS and non-ACS 
group were 2.15 ± 0.36 and 2.14 ± 0.35 respectively. Sim-
ilar mean lesion length of around 15.5 mm was recorded 
in both groups. The LAD was the most common target 
vessel for both the ACS and non-ACS group. The distri-
bution of coronary arteries treated were similar for both 
groups. In terms of lesion characteristics, the ACS group 
had more acute total occlusion (15.1 vs 7.4 %, p = 0.015) 
and higher thrombus burden rate (13.2 vs 0.3  %, p = 
0.001). The degree of stenosis is also higher in the ACS 
group (88.5 vs 84.5 %, p = 0.001). Apart from the above, 
both ACS and non-ACS group have no significant differ-
ence in coronary artery complexity. Additional stenting 
was required in 9.3 % ACS and 6.5 % non-ACS, p = 0.308. 
Reasons for additional stenting were target lesion related 
dissection (57.6 %) or non-target lesion stenosis (41.2 %).
Periprocedure anti‑platelet therapy
All patients were on aspirin. Clopidogrel was the most 
common second anti-platelet drug followed by prasugrel, 
ticagrelor and ticlopidine. A small minority of patients 
were on single antiplatelet aspirin (5.7 % ACS and 4.7 % 
non-ACS). No significant difference in the ACS and 
non-ACS groups in terms of periprocedural anti-platelet 
therapy (Tables 2, 3, 4).  
Duration of dual anti‑platelet therapy (DAPT) during follow 
up
More than half of the patients had 4  weeks of aspirin/
clopidogrel (57.1  % ACS, 60.5  % non-ACS). No signifi-
cant difference between the ACS and non-ACS groups 
with regards to the duration and types of DAPT during 
follow up.
Clinical outcome
Table  5 illustrates the clinical outcome of the patients. 
The primary end-point of 9 months TLR were 1.2 % ACS 
versus 4.3  % non-ACS (p =  0.180). Overall, the MACE 
rate at 9 months was 4.7 % for the entire registry. MACE 
rates were 0  % at 30-day and 3.6  % at 9  months in the 
ACS group. The rates were lower as compared to the 
non-ACS group, but were not significantly different. No 
cases of target lesion/vessel or non-target vessel throm-
bosis reported in the ACS group.
Discussion
The definition of small vessel from the literature varies. 
For our registry, we took the cut-off point of 2.75  mm 
or less as small vessel. From coronary revascularisation 
point of view, small vessel PCIs make up a significant 
portion constituting to about 35–45 % of all PCIs (Zey-
mer and Scheller 2011). PCI with stenting in small vessels 
remains challenging as the outcome is poorer compared 
to PCI of larger vessels. Small vessels have less tolerance 
to neointimal proliferation post stent implantation (Hau-
sleiter et al. 2002; Agostoni et al. 2005). The risk of ISR in 
small vessels even with the introduction of DES stents is 
still considered significant (Meier et al. 2006; Togni et al. 
2007). This is in addition to the already known complica-
tion of stent thrombosis.
PCB angioplasty in small vessels was first reported 
in 2010 which showed a TLR rate of 4.9  % in PCB 
only patients (n  =  73) with reference diameter of 
2.36  ±  0.18  mm and lesion lengths of 11.3  ±  4.3  mm 
(Unverdoben et al. 2010). After the initial failure of PIC-
COLETTO study trial (Cortese et  al. 2010) to show a 
non-inferiority of PCB versus DES, came a larger ran-
domised trial comparing PCB and DES in small vessel de 
novo lesions (BELLO study) (Latib et  al. 2012). BELLO 
study comprising 182 patients, showed superiority of 
PCB over TAXUS stents in terms of late lumen loss (LLL) 
and similar angiographic restenosis, target lesion revas-
cularisation and MACE rates at 6 months. Patients from 
the BELLO study were then followed up for 2 years and 
showed better TLR rates (compared to PES TAXUS) at 
Table 1 Patient demographics and presentations
PCI percutaneous coronary intervention, CABG coronary artery bypass graft, 
STEMI ST-elevation myocardial infarction, NSTEMI non-ST elevation myocardial 
infarction
Variable All patients non ACS ACS p value
Number of patients 447 334 113 –
Number of lesions 471 365 106 –
Age (years) 66.1 ± 10.9 66.2 ± 10.2 65.9 ± 12.9 0.761
Male gender 324 (72.5 %) 247 (72.2 %) 77 (73.3 %) 0.824
Diabetes 164 (36.7 %) 128 (37.4 %) 36 (34.3 %) 0.559
Hypertension 360 (80.5 %) 281 (82.2 %) 79 (75.2 %) 0.117
Hyperlipidemia 308 (68.9 %) 244 (71.3 %) 64 (61.0 %) 0.044
History of smoking 169 (37.8 %) 128 (37.4 %) 41 (39.0 %) 0.765
Renal insufficiency 44 (9.8 %) 32 (9.4 %) 12 (11.4 %) 0.533
Prior PCI 238 (53.2 %) 193 (56.4 %) 45 (42.9 %) 0.015
Prior CABG 44 (9.8 %) 34 (9.9 %) 10 (9.5 %) 0.900
Atrial fibrillation 41 (9.2 %) 31 (9.1 %) 10 (9.5 %) 0.887
Age group ≥75 year 113 (25.3 %) 84 (24.6 %) 29 (27.6 %) 0.528
STEMI 41 (9.2 %) 0 (0.0 %) 41 (39.0 %) –
NSTEMI 64 (14.3 %) 0 (0.0 %) 64 (61.0 %) –
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6 months (4.4 vs 7.6 %), 1 year (6.7 vs 12.1 %) and 2 years 
(6.8 vs 12.1 %) (Naganuma et al. 2015).
Stent implantation is considered the standard and well 
established treatment for ACS (Windecker et al. 2014) to 
improve clinical outcome. However PCI in ACS in small 
vessels is not spared from the issue of high ISR rate and 
stent thrombosis. Evidence of PCB specifically in ACS 
is still sparse. Besic et al. (2015) reported a significantly 
lower LLL of PCB  +  BMS combination compared to 
BMS alone at 6  months but no significant difference in 
MACE and binary LLL and ISR were noted.
There is now rather convincing data on the efficacy 
and safety of PCB in small vessels de novo lesions in 
general (Zeymer et al. 2014). However its use in ACS in 
Table 2 Lesion characteristics and procedural data in ACS and non-ACS patients
LAD left anterior descending artery, LCX left circumflex artery, RCA right coronary artery, AHA/ACC American Heart Association/American College of Cardiology, DEB 
drug eluting balloon
Variable All patients Non ACS ACS p value
Number of lesions 471 353 118 –
Target vessel
 LAD 193 (41.0 %) 154 (42.2 %) 39 (36.8 %) 0.128
 LCX 126 (26.8 %) 91 (24.9 %) 35 (33.0 %)
 RCA 94 (20.0 %) 69 (18.9 %) 25 (23.6 %)
 Ramus intermedius 19 (4.0 %) 17 (4.7 %) 2 (1.9 %)
 Other 39 (8.9 %) 34 (9.3 %) 5 (4.7 %)
Lesion characteristics
 Total occlusion 43 (9.1 %) 27 (7.4 %) 16 (15.1 %) 0.015
 Chronic total occlusion 16 (3.4 %) 13 (3.6 %) 3 (2.8 %) 0.714
 Thrombus burden 15 (3.2 %) 1 (0.3 %) 14 (13.2 %) <0.001
 Diffuse vessel disease 200 (57.5 %) 156 (42.7 %) 44 (41.5 %) 0.822
 Calcification 112 (23.8 %) 83 (22.7 %) 29 (27.4 %) 0.325
 Vein graft 9 (1.9 %) 8 (2.2 %) 1 (0.9 %) 0.409
 Ostial lesion 48 (10.2 %) 35 (9.6 %) 13 (12.3 %) 0.423
 Bifurcation lesion 45 (9.6 %) 35 (9.6 %) 10 (9.4 %) 0.962
 Severe tortuosity 45 (9.6 %) 32 (8.8 %) 13 (12.3 %) 0.281
 AHA/ACC type B2/C lesion 182 (38.6 %) 133 (36.4 %) 49 (46.2 %) 0.068
 Reference diameter (mm) 2.14 ± 0.35 2.14 ± 0.35 2.15 ± 0.36 0.973
 Lesion length 15.5 ± 7.0 15.5 ± 7.3 15.6 ± 5.9 0.926
 Degree of stenosis (%) 85.3 ± 11.2 84.5 ± 11.4 88.5 ± 10.2 0.001
Procedural data
 Predilation device diameter (mm) 2.02 ± 0.25 2.01 ± 0.24 2.04 ± 0.29 0.303
 Predilatation device length (mm) 15.6 ± 4.5 15.7 ± 4.6 15.5 ± 4.3 0.655
 Predilatation device pressure (atm) 11.8 ± 3.1 11.8 ± 3.2 11.7 ± 3.1 0.941
 DEBs used 478 371 107 –
 DEBs per patient 1.07 ± 0.29 1.08 ± 0.32 1.03 ± 0.17 0.114
 DEB diameter (mm) 2.33 ± 0.31 2.32 ± 0.30 2.37 ± 0.32 0.138
 DEB length (mm) 19.2 ± 4.5 19.2 ± 4.5 18.8 ± 4.3 0.425
 DEB inflation pressure (atm) 11.0 ± 3.4 10.9 ± 2.8 11.3 ± 4.9 0.352
 DEB inflation time (s) 48.5 ± 15.9 48.5 ± 16.0 48.6 ± 15.6 0.982
 Additional stent 34 (7.2 %) 24 (6.5 %) 10 (9.3 %) 0.308
 Overall technical success per used device (n = 478) 473 (99.0 %) 368 (99.2 %) 105 (98.1 %) 0.342
Table 3 Peri-procedural antiplatelet therapy in  ACS 
and non-ACS patients
GP IIb/IIIA glycoprotein IIb/IIIa
Variable All patients Non ACS ACS p value
Aspirin 447 (100 %) 334 (100 %) 113 (100 %) –
 Clopidogrel 364 (81.4 %) 277 (81.0 %) 87 (82.9 %) 0.792
 Prasugrel 41 (9.2 %) 32 (9.4 %) 9 (8.6 %)
 Ticagrelor 8 (1.8 %) 6 (1.8 %) 2 (1.9 %)
 Ticlopidine 4 (0.9 %) 4 (1.2 %) 0 (0.0 %)
Aspirin + vitamin K 
antagonists
9 (2.0 %) 8 (2.3 %) 1 (1.0 %)
Aspirin only 21 (4.7 %) 15 (4.4 %) 6 (5.7 %)
GP IIb/IIIa inhibitors 10 (2.2 %) 8 (2.3 %) 2 (1.9 %) 0.792
Page 5 of 6Mahmood Zuhdi et al. SpringerPlus  (2016) 5:373 
particular is still unclear. Ho et al. (2015) reported MACE 
rate of 4.5  % in PCB primary angioplasty of STEMI at 
30-day follow up. Our study shows the outcome of PCB 
in ACS and non-ACS is comparably similar in small ves-
sel de novo lesions. MACE rate at 30-days and 9-months 
follow up showed a better trend in ACS than the non-
ACS group. MACE at 30  days is 0.3  % non-ACS versus 
0 % ACS and 9-months MACE is 5.0 % non-ACS versus 
3.6 % ACS. In comparison to other small vessel de novo 
lesion studies, TLR at 9-months follow up was reported 
as 3.6  % (PCB only) and 4.0  % (PCB  +  BMS) (Zeymer 
et al. 2014) and 1 % (PCB only) and 2.4 % (PCB + BMS) 
(Wohrle et al. 2012). The mean vessel diameter difference 
for the two above studies might explain the lower rate of 
TLR.
Conclusion
The use of PCB in ACS of small vessel de novo lesion is 
associated with a low TLR/MACE rate comparable to 
small vessel PCB angioplasty in general. This suggests 
PCB angioplasty in ACS is a feasible alternative to stent 
implantation in ACS.
Study limitation
Since the purpose of this observational study was the 
documentation of PCB angioplasty in the clinical rou-
tine, event underreporting may have occured. In this 
context, the procedural details could have been specified 
in more detail as well. For instance in case of thrombus 
burden the type of the aspiration device would have been 
highly desirable. Furthermore, in the case of PCB angio-
plasty one needs to point out that the learning curve to 
treat small lesions with PCB only requires positive clini-
cal feedback of each investigator. This entails a learning 
curve to accept angiographically ‘unpleasing’ results for 
the benefit of having no implant in a small vessel. How-
ever, due to the level of each investigator’s experience a 
selection bias could not be ruled out in this assessment.
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Table 4 Duration of dual antiplatelet therapy during follow-up in ACS and non-ACS patients
Variable All patients Non ACS ACS p value
Number of patients 447 334 113 –
4 weeks aspirin 100 mg + clopidogrel 267 (59.7 %) 207 (60.5 %) 60 (57.1 %) 0.385
3 months aspirin 100 mg + clopidogrel 5 (1.2 %) 5 (1.5 %) 0 (0.0 %)
6–12 months aspirin 100 mg + clopidogrel 68 (15.2 %) 52 (15.2 %) 16 (15.2 %)
12 months aspirin 100 mg + clopidogrel 70 (15.7 %) 47 (13.7 %) 23 (21.9 %)
Aspirin 100 mg + clopidogrel life long 2 (0.4 %) 2 (0.6 %) 0 (0.0 %)
12 months aspirin 100 mg + prasugrel 3 (0.7 %) 2 (0.6 %) 1 (1.0 %)
12 months aspirin 100 mg + ticagrelor 3 (0.7 %) 2 (0.6 %) 1 (1.0 %)
Unknown 29 (6.5 %) 24 (7.0 %) 5 (4.8 %)
Table 5 Clinical outcomes in  patient populations in  ACS 
and non-ACS patients
MACE major adverse cardiac events, TLR target lesion revascularisation, MI 
myocardial infarction
Variable All patients Non ACS ACS p value
Number of patients 447 334 113 –
Patients with clinical 
follow-up
384 (85.9 %) 301 (90.3 %) 83 (73.5 %) 0.021
Follow-up time 
(months)
9.4 ± 1.7 9.5 ± 1.7 9.4 ± 1.6 0.875
30-day MACE 1 (0.3 %) 1 (0.3 %) 0 (0.0 %) 0.599
30-day TLR 1 (0.3 %) 1 (0.3 %) 0 (0.0 %) 0.599
30-day MI 1 (0.3 %) 1 (0.3 %) 0 (0.0 %) 0.599
30-day cardiac death 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) –
9-month MACE 18 (4.7 %) 15 (5.0 %) 3 (3.6 %) 0.601
9-month TLR 14 (3.6 %) 13 (4.3 %) 1 (1.2 %) 0.180
9-month MI 7 (1.8 %) 4 (1.3 %) 3 (3.6 %) 0.168
9-month cardiac 
death
0 (0.0 %) 0 (0.0 %) 0 (0.0 %) –
9-month vessel 
thrombosis
3 (0.8 %) 3 (1.1 %) 0 (0.0 %) 0.356
 Target lesion 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) –
 Target vessel 2 (0.5 %) 2 (0.7 %) 0 (0.0 %) 0.457
 Non-target vessel 1 (0.3 %) 1 (0.3 %) 0 (0.0 %) 0.599
Page 6 of 6Mahmood Zuhdi et al. SpringerPlus  (2016) 5:373 
Competing interests
Dr. Mathhias Waliszewski and Dr. Michael Boxberger are from the B. Braun’s 
Medical Scientific Affairs, Berlin Germany.
Consent
Written informed consent was obtained from the patients for publication of 
this manuscript. A copy of the written consent is available for review by the 
Editor-in-Chief of this journal.
Received: 26 January 2016   Accepted: 16 March 2016
References
Agostoni P, Biondi-Zoccai GGL, Gasparini GL, Anselmi M, Morando G, Turri M 
et al (2005) Is bare-metalstenting superior to balloon angioplasty for 
small vessel coronary arterydisease? Evidence from a meta-analysis of 
randomized trials. Eur Heart J 26:881–889
Akiyama T, Moussa I, Reimers B (1998) Angiographic and clinical outcome 
following coronary stenting of small vessels a comparison with coronary 
stenting of large vessels. J Am Coll Cardiol 32:1610–1618
Ali RM, Degenhardt R, Zambahari R, Tresukosol D, Ahmad WA, Hb Kamar et al 
(2011) Paclitaxel-eluting balloon angioplasty and cobalt-chromium stents 
versus conventional angioplasty and paclitaxel eluting stents in the 
treatment of native coronary artery stenoses in patients with diabetes 
mellitus. Eurointervention 7(suppl k):K61–K65
Besic KM, Strozzi M, Margetic E, Bulum J, Kolaric B (2015) Drug-eluting balloons 
in patients with non-ST elevation acute coronary syndrome. J Cardiol 
65(3):203–207
Byrne RA, Neumann J, Mehilli J, Pinieck S, Wolff B, Tiroch K et al (2013) 
Paclitaxel eluting balloons, paclitaxel eluting stents and balloon 
angioplasty in patients with restenosis after implantation of a drug-
eluting stent (ISAR-DESIRE 3): a randomised, open label trial. Lancet 
381:461–467
Cortese B, Micheli A, Picchi A, Coppolaro A, Bandinelli L, Severi S et al (2010) 
PICCOLETO Study prospective randomised clinical trial. The stent during 
PCI of small coronary vessels, a paclitaxel-coated balloon versus drug 
eluting. Heart 96:1291–1296
Cutlip D, Windecker S, Mehran R (2007) Clinical end points in coronary stent 
trials: a case for standardized definitions. Circulation 115:2344–2351
Harbara S, Mitsudo K, Kadota K, Goto T, Fujii S, Yamamoto H et al (2011) Effec-
tiveness of paclitaxel-eluting balloon catheter in patients with sirolimus-
eluting stent restenosis. J Am Coll Cardiol Intv 4:149–154
Hausleiter J, Kastrati A, Mehilli J, Dotzer F, Schühlen H, Dirschinger J et al (2002) 
Comparative analysis of stentplacement versus balloon angioplasty in 
small coronary arteries withlong narrowings (the Intracoronary Stenting 
or Angioplasty for Restenosis Reduction in Small Arteries [ISAR-SMART] 
Trial). Am J Cardiol 89:58–60
Ho HH, Tan J, Ooi YW, Loh KK, Aung TH, Yin NT et al (2015) Preliminary experi-
ence with drug-coated balloon anggiopasty in primary percutaneous 
coronary intervention. World J Cardiol 7(6):311–314
Kasaoka A, Tobis JM, Akiyama T (1998) Angiographic and intravascular ultra-
sound predictors of in-stent restenosis. J Am Coll Cardiol 32:1630–1635
Kleber FX, Mathey DG, Rittger H, Scheller B, German Drug-eluting Balloon 
Consensus Group (2011) How to use the drug-eluting balloon: recom-
mendations by the German consensus group. Eurointervention 7(suppl 
K):K125-8
Latib A, Colombo A, Castriota F, Micari A, Cremonesi A, De Felice F et al (2012) 
A randomised multicenter study comparing a paclitaxel drug-eluting bal-
loon with a paclitaxel eluting stent in small coronary vessels: the BELLO 
(Balloon Elution and Late Loss optimization) study. J Am Coll Cardiol 
60:2473–2480
Meier B, Sousa E, Guagliumi G, Van den Branden F, Grenadier E, Windecker S 
et al (2006) Sirolimus eluting stents in small vessels. Am Heart J 151:1019
Naganuma T, Latib A, Squeglia GA, Menozzi A, Castriota F, Micari A et al (2015) 
A 2-year follow-up of a randomized multicenter study comparing a 
paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small 
coronary vessels the BELLO study. Int J Cardiol 184:17–21
Scheller B, Herlein C, Bocksch W et al (2006) Treatment of in-stent restenosis 
with a paclitaxel-coated balloon catheter. N Eng J Med 355:2113–2124
Scheller B, Herlein C, Bocksch W, Rutsch W, Haghi D, Dietz U et al (2008) Two 
year follow-up after treatment of coronary in-stent restenosis with a 
paclitaxel-coated balloon catheter. Clin Res Cardiol 97:773–781
Scheller B, Clever YP, Kelsch B, Herlein C, Bocksch W, Rutsch W et al (2012) Long 
term follow up after treatment of in-stent restenosis with a paclitaxel-
coated balloon catheter. J Am Coll Cardiol Intv 5(3):323–330
Togni M, Eber S, Widmer J, Billinger M, Wenaweser P, Cook S et al (2007) Impact 
of vessel size on outcome after implantation of sirolimus-eluting and 
paclitaxel-eluting stents. J Am Coll Cardiol 50:1123–1131
Unverdoben M, Kleber FX, Heuer H, Figulla HR, Vallbracht C, Leschke M et al 
(2010) Treatment of small coronary arteries with a paclitaxel balloon 
catheter. Clin Res Cardiol 99(3):165–174
Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J et al (2014) 2014 ESC/EACTS 
Guidelines on myocardial revascularization: the Task Force on Myocardial 
Revascularization of the European Society of Cardiology (ESC) and the 
European Association for Cardio-Thoracic Surgery (EACTS)Developed 
with the special contribution of the European Association of Percutane-
ous Cardiovascular Interventions (EAPCI). Eur Heart J 35:2541–2619
Wohrle J, Zadura M, Mobius-Winkler S, Leschke M, Opitz C, Ahmed W et al 
(2012) SeQuent please world wide registry: clinical results of SeQuent 
please paclitaxel-coated balloon angioplasty in a large-scale, prospective 
registry study. J Am Coll Cardiol 60:1733–1738
Zeymer U, Scheller B (2011) PCI in small vessels: the case for a drug-coated 
balloon based intervention. Eurointervention 7(Suppl K):K57–K60
Zeymer U, Waliszewski M, Spiecker M, Gastmann O, Ferrari B, Ferrari M et al 
(2014) Prospective ‘real world’ registry for the use of ‘PCB only’ strategy in 
small vessel de novo lesions. Heart 100:311–316
